Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

National Institute for Health and Care Excellence NICE logo

NICE turns down Keytruda for lung cancer in draft guidance

Says long-term benefits for advanced non-small cell lung cancer treatment not proven

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

UK to establish a digital academy for healthcare professionals

NHS technology plans will also see 12 trusts act as digitisation pioneers

- PMLiVE

NHS promotes person-centred care in new dementia film

Highlights the importance of enabling people to live well with the condition

- PMLiVE

NHS goes global with ‘Missing Type’ blood donor campaign

High profile brand partnership has already involved the likes of Microsoft, Waterstones and the RAF

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

- PMLiVE

Portrait exhibition raises refugee healthcare profile

Doctors of the World opens gallery to mark 10-year anniversary of its London clinic

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links